skip to content


Issue No. 10 | April 5, 2013

News and Features

Correction to the Perinatal Guidelines Issued

On April 3, 2013, an error in the references in the Darunavir section was corrected. Reference 4 was updated. To view the correction notice, please click here.

NIH-Funded Scientists Map Possible Path to an HIV Vaccine

“In an advance for HIV vaccine research, scientists have for the first time determined how both the virus and a resulting strong antibody response co-evolved in one HIV-infected individual. The findings could help researchers identify which proteins to use in investigational vaccines to induce antibodies capable of preventing infection from an array of HIV strains. …

“In the current study, scientists identified one of the roughly 20 percent of HIV-infected individuals who naturally develop broadly neutralizing antibodies to the virus after several years of infection. This person in Africa was a volunteer in a study in which participants gave weekly blood samples beginning early in the course of infection. This individual had joined the study just 4 weeks after infection and was followed for more than 3 years. Having blood samples from such an early stage enabled researchers to pinpoint the particular ‘founder’ virus that triggered the immune system to make an immature broadly neutralizing antibody against HIV, as well as the cell from which that antibody emerged. Analyses of the weekly samples also enabled the scientists to see the series of changes that the virus and antibody underwent over 2.5 years until the antibody matured to a form capable of potently neutralizing the virus. Scientists are now attempting to create a vaccine that harmlessly mimics the virus at key points in the observed process to generate broadly neutralizing HIV antibodies, first in uninfected animals and then in uninfected people.”

More information is available:

AIDSinfo Glossary Offers Definitions for More Than 700 HIV/AIDS-Related Terms

The AIDSinfo Glossary of HIV/AIDS-Related Terms offers concise definitions for more than 700 HIV/AIDS-related terms. The glossary is available in English and Spanish in a variety of formats, including on Apple or Android devices via the AIDSinfo glossary app. Ranked among the 10 best HIV apps by Healthline, the glossary app provides access to the same terms found in the online and print versions of the glossary.

Additional features of the glossary include appendices that list common abbreviations and acronyms, contact information for HIV/AIDS-related resources, and FDA-approved antiretroviral drugs organized by drug class. Users viewing the glossary online via the full and mobile AIDSinfo and infoSIDA websites or on mobile devices via the glossary app can toggle between the English and Spanish definitions of terms and hear terms pronounced in both languages.

Visit AIDSinfo and infoSIDA to view the glossary, order a print copy of the glossary, or download the free glossary app.